It's another week of debate over PBS deferrals. Unfortunately, there appears to be an effort to limit public discussion. Given the obvious risk to patients and the implications for the access agenda, which is flailing against the backdrop of deferrals, how does that make sense? It also stands in stark contrast to when cost recovery was introduced. …
Latest Video
New Stories
-
PYC to present early polycystic kidney disease trial data at US nephrology conference
October 7, 2026 - - Australian Biotech -
CSL raises US$1.5 billion from US bond investors to refinance debt
October 7, 2026 - - Latest News -
Every serious attempt to reform PBS pricing has run into the same problem
October 7, 2026 - - Latest News -
AFT reaffirms profit guidance as its R&D pipeline moves toward 2029 launches
October 7, 2026 - - Latest News -
The patient who knows what they want is informed and not a danger
October 7, 2026 - - Latest News -
TGA turns to national security surveillance platform to police therapeutic goods compliance
October 6, 2026 - - Latest News -
Company size shapes CEO pay trends in Australian health care and biotechnology
October 6, 2026 - - Latest News